bluuebunny/crossref_metadata_2025_split huggingface dataset:
Eating, looking, and living clean: Techniques of white femininity in contemporary neoliberal food culture
Authors: Wilkes Karen 
Published: January 2021

AbstractThis article contributes to Gender Work and Organization's Special Themed Section on Foodwork, by addressing the intersections of race, gender, and class in representations of labor, whiteness, and neoliberalism in popular and digital food cultures. The discussion responds to the journal's call for papers by examining the clean eating trend as a vehicle for the ideals of white femininity, and the techniques of femininity that are employed to convey messages of normalcy and exceptionalism in this contemporary popular food culture. In the analysis of an article in the high‐end home interiors magazine, Elle Decoration, the visual authoritativeness of clean eating advocates is considered to highlight the strategies and devices used to deploy ideals of white femininity and to create boundaries around a remodeled white female neoliberal self. The article aims to advance current debates regarding digital foodwork, by examining the esthetics of whiteness that are contained within the message of relatability communicated by social media food influencers. Thus, in keeping with the broader concerns of the journal, the article addresses developments in the fields of gender and digital labor, with respect to the overwhelming dominance of privileged white women in this sphere and the esthetics of their labor, which has thus far received limited attention within existing debates.
Management of primary headaches during pregnancy, postpartum, and breastfeeding: A systematic review
Authors: Saldanha Ian J. , Cao Wangnan , Bhuma Monika Reddy , Konnyu Kristin J. , Adam Gaelen P. , Mehta Shivani , Zullo Andrew R. , Chen Kenneth K. , Roth Julie L. , Balk Ethan M. 
Published: January 2021

AbstractBackgroundPrimary headaches (migraine, tension headache, cluster headache, and other trigeminal autonomic cephalgias) are common in pregnancy and postpartum. It is unclear how to best and most safely manage them.ObjectiveWe conducted a systematic review (SR) of interventions to prevent or treat primary headaches in women who are pregnant, attempting to become pregnant, postpartum, or breastfeeding.MethodsWe searched Medline, Embase, Cochrane CENTRAL, CINAHL, ClinicalTrials.gov, Cochrane Database of SRs, and Epistemonikos for primary studies of pregnant women with primary headache and existing SRs of harms in pregnant women regardless of indication. No date or language restrictions were applied. We assessed strength of evidence (SoE) using standard methods.ResultsWe screened 8549 citations for studies and 2788 citations for SRs. Sixteen studies (mostly high risk of bias) comprising 14,185 patients (total) and 26 SRs met the criteria. For prevention, we found no evidence addressing effectiveness. Antiepileptics, venlafaxine, tricyclic antidepressants, benzodiazepines, β‐blockers, prednisolone, and oral magnesium may be associated with fetal/child adverse effects, but calcium channel blockers and antihistamines may not be (1 single‐group study and 11 SRs; low‐to‐moderate SoE). For treatment, combination metoclopramide and diphenhydramine may be more effective than codeine for migraine or tension headache (1 randomized controlled trial; low SoE). Triptans may not be associated with fetal/child adverse effects (8 nonrandomized comparative studies; low SoE). Acetaminophen, prednisolone, indomethacin, ondansetron, antipsychotics, and intravenous magnesium may be associated with fetal/child adverse effects, but low‐dose aspirin may not be (indirect evidence; low‐to‐moderate SoE). We found insufficient evidence regarding non‐pharmacologic treatments.ConclusionsFor prevention of primary headache, calcium channel blockers and antihistamines may not be associated with fetal/child adverse effects. For treatment, combination metoclopramide and diphenhydramine may be more effective than codeine. Triptans and low‐dose aspirin may not be associated with fetal/child adverse effects. Future research should identify effective and safe interventions in pregnancy and postpartum.
The genesis of private dispute resolution in Irish industrial relations
Authors: Roche William K. 
Published: January 2021

AbstractThis article examines the genesis of private dispute resolution arrangements introduced by employers and unions in Ireland. These forms of collective alternative dispute resolution (ADR) comprise three‐person panels or sole adjudicators, who mediate and issue findings on collective disputes. Findings may be non‐binding or binding. Using data and interviews covering 11 private dispute resolution arrangements in 10 organisations, the paper identifies the circumstances in which they have emerged and a series of influences that lead employers and unions make path‐breaking changes in dispute resolution procedures.
Coproduction Challenges in the Context of Changing Rural Livelihoods
Authors: Popovici Ruxandra , Mazer Katy E. , Erwin Anna E. , Ma Zhao , Cáceres José P. Pinto , Bowling Laura C. , Bocardo‐Delgado Edwin F. , Prokopy Linda S. 
Published: January 2021

AbstractCoproduction is a process that involves scientists and citizens engaging throughout the production of knowledge, decisions, and/or policies. This approach has been widely applied in an international context for addressing global environmental issues. It is customary for scientists to travel to rural communities, where both scientists and local knowledge holders work together and jointly design solutions to pressing problems. Such collaboration, however, often involves high costs for both residents and scientists, which can reduce project effectiveness. This study examines the challenges associated with coproduction in the context of changing rural livelihoods in beneficiary communities. We specifically conduct a self‐analysis of the coproduction process led by our own university team, where scientists designed tools for water and crop management together with community members in Peru's Caylloma province. We collected qualitative data on the coproduction challenges in five local districts in Caylloma, using focus groups and semi‐structured interviews. Our results indicate that changing socioeconomic conditions in rural communities undermined the long‐term sustainability and effectiveness of the coproduction efforts and deliverables. These included increased migration, market integration, and reliance on regional institutions for water and crop management.
Multipath optical thermometry realized in CaSc2O4: Yb3+/Er3+ with high sensitivity and superior resolution
Authors: Xiang Guotao , Xia Qing , Xu Su , Liu Xiuchong , Jiang Sha , Wang Yongjie , Zhou Xianju , Li Li , Ma Li , Wang Xiaojun , Zhang Jiahua 
Published: January 2021

AbstractDesign and fabrication of contactless optical thermometer with rapid and accurate performance has become a research hotspot in recent years. Herein, CaSc2O4: Yb3+/Er3+ is employed as the intermediary for temperature sensing under the excitation of 980 nm, which is proven to afford an ultra‐sensitive and high‐resolution optical thermometry in multiple ways based on the fluorescence intensity ratio (FIR) technology. The optimal thermal sensing behaviors are realized by the FIR of Er3+:2H11/2 → 4I15/2 to 4S3/2 → 4I15/2 transition, which has a relative sensitivity of 1184/T2 and a minimal resolution of 0.03 K along with a maximal absolute error of 0.96 K. Besides that, the FIR between the thermally coupled Stark sublevels of Er3+:4F9/2 manifold (FIRR) as well as that of Er3+: 4I13/2 manifold (FIRN) can also provide excellent optical thermometry. The relative sensitivity of FIRR‐based and FIRN‐based optical thermometers are calculated to be 402/T2 and 366/T2, respectively, with a same minimal resolution of 0.09 K, which possess the potential to be used for biomedicine due to the inherent advantage of their operating wavelengths located in the biological window. The results demonstrate that CaSc2O4: Yb3+/Er3+ is a promising candidate for temperature sensing with multipath, high sensitivity, and superior resolution.
Features and diversity of symptoms of moyamoya disease in adolescents: A cluster analysis
Authors: Oh Won‐Oak , Shim Kyu Won , Yeom Insun , Park Il Tae , Heo YooJin 
Published: January 2021

AbstractAimsThe purpose of this study is to explore the symptoms experienced by adolescents with moyamoya disease and to identify the characteristics of each symptom cluster associated with moyamoya disease.DesignA retrospective and descriptive design, which is a secondary data analysis study based on electronic medical record data from hospitals.MethodsTo assess the symptoms associated with moyamoya disease, a qualitative study was conducted on 12 adolescents, 12 caregivers and 12 experts on moyamoya disease. According to a qualitative study, 12 main symptoms (limb weakness, numbness, pins and needles, difficulty in speech, blurred vision, facial paralysis, hand tremors, involuntary movements, convulsions, dizziness, nausea/vomiting and headaches) were selected. Data were collected around these symptoms. The data collection was carried out through the Electronic Medical Record (EMR) data of 303 adolescents aged 13–19 who were diagnosed with moyamoya disease (ICD 10 Code: I67.5) between January 2010–December 2019 in a hospital in Seoul, South Korea. Cluster analysis was applied to identify symptom clusters with the hierarchical cluster agglomerative approach. We used the log‐likelihood distance to measure the similarity of variables. Proximity between groups of variables was measured using the two‐step method.ResultsThe physical symptoms experienced by adolescents with moyamoya disease were ‘limb weakness’ – the most common – followed by a ‘headache,’ ‘difficulty in speech,’ and ‘nausea/vomiting.’ A total of five symptom clusters were derived: cluster 1 was characterized by ‘limb weakness’; cluster 2 participants were asymptomatic or experienced ‘convulsions’; cluster 3 experienced ‘difficulty in speech’ and ‘facial paralysis’; cluster 4 is prone to ‘dizziness’ and ‘pins and needles’; and cluster 5 displays ‘headaches’ and ‘nausea/vomiting’.ConclusionThis study offers a multidimensional approach for identifying differences in clinical symptoms of moyamoya disease among adolescents.ImpactThese results will help provide interventions concerning the characteristics of the symptoms of moyamoya disease among adolescents.
The family transition experience when living with childhood neuromuscular disease: A grounded theory study
Authors: Waldboth Veronika , Patch Christine , Mahrer‐Imhof Romy , Metcalfe Alison 
Published: January 2021

AbstractAimsNeuromuscular diseases are rare conditions that present with progressive muscular weakness. As affected children transition into adulthood, they become more physically dependent on their families for support. There is little evidence on the family transition experience, which this study explored to identify experiences, challenges, and strategies of coping.DesignInformed by family systems theory, a constructivist grounded theory study was conducted (2014–2017).MethodsData were collected by one‐on‐one interviews with a purposive sample of affected Swiss individuals and their families from 2015 to 2016. Data analysis used coding, memo writing, theoretical sampling, and constant comparison techniques.ResultsThe analysis of 31 interviews with 10 affected individuals and 21 family members resulted in an interpretive theory constituted of four categories: (a) living with physical dependence, while striving for independence; (b) balancing proximity; (c) conforming and challenging social standards and expectations; and (d) grieving for loss, while joining forces for life.ConclusionFamily functioning and well‐being were threatened by recurring tension from stress, physical and emotional difficulties, strained relationships, and conflict. The families’ strategies of coping and adaptation and their relationships and communication shaped their transition experience.ImpactFamilies that experience threats to their well‐being and functioning would benefit from: needs assessment and monitoring; planning of appropriate family interventions; support of family relationships and communication, effective coping, and mastery; and positive adaptation to change.
Transcatheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy: Long‐term results and clinical outcomes
Authors: Castagno Davide , Di Donna Paolo , Olivotto Iacopo , Frontera Antonio , Calò Leonardo , Scaglione Marco , Arretini Anna , Anselmino Matteo , Giustetto Carla , De Ferrari Gaetano Maria , Cecchi Franco , Haissaguerre Michel , Gaita Fiorenzo 
Published: January 2021

AbstractIntroductionRadiofrequency transcatheter ablation (RFCA) for atrial fibrillation (AF) in patients with hypertrophic cardiomyopathy (HCM) has been proven feasible. However, the long‐term results of RFCA and its impact on clinical course of HCM are unknown. The aim of this study was to analyse clinical outcomes and long‐term efficacy of RFCA in a multicentre cohort of patients with HCM and concomitant AF.MethodsPatients with HCM and AF consecutively undergoing RFCA were included. Ablation failure was defined as recurrence of AF, atrial tachycardia, or flutter lasting more than 3 min and occurring after the blanking period.ResultsOverall, 116 patients with symptomatic AF refractory to antiarrhythmic drugs were included. Over a median follow‐up of 6.0 years (interquartile range: 3.0–8.9 years) recurrence rate after a single RFCA was 32.3 per 100 patient/years with 26% of patients free from AF relapses at 6‐year follow‐up. Among patients experiencing AF recurrence, 51 (66%) underwent at least one redo‐procedure. The overall recurrence rate considering redo‐procedures was 12.6 per 100 patients/years with 53% of patients free from AF relapses at 6 years. At last follow‐up, with an average of 1.6 procedures, 67 (61%) patients were in sinus rhythm (SR). Patients remaining in SR showed better functional status compared with those experiencing arrhythmic recurrences (NYHA Class 1.6 ± 0.1 vs. 2.0 ± 0.1, p = .009).ConclusionsRFCA of AF in HCM patients is an effective and safe strategy favoring long‐term SR maintenance, reduction of atrial arrhythmic events, and improved functional status. However, most patients need repeat procedures and continuation of antiarrhythmic drugs.
Neferine suppresses autophagy‐induced inflammation, oxidative stress and adipocyte differentiation in Graves' orbitopathy
Authors: Li Hong , Gao Long , Min Jie , Yang Yucheng , Zhang Ren 
Published: January 2021

AbstractPrevious studies in Graves’ orbitopathy (GO) patient‐derived fibroblasts showed that inhibition of autophagy suppresses adipogenic differentiation. Autophagy activation is associated with inflammation, production of reactive oxygen species and fibrosis. Neferine is an alkaloid extracted from Nelumbo nucifera, which induces Nrf2 expression and inhibits autophagy. Here, we have elucidated the role of neferine on interleukin (IL)‐13‐induced autophagy using patient‐derived orbital fibroblasts as an in vitro model of GO. GO patient‐derived orbital fibroblasts were isolated and cultured to generate an in vitro model of GO. Autophagy was determined by Western blot detection of the markers such as Beclin‐1, Atg‐5 and LC3 and by immunofluorescence detection of autophagosome formation. Analysis of differentiation towards an adipogenic lineage was performed by Oil red O staining. The expression of inflammatory factors was detected by ELISA and semiquantitative RT‐PCR. Neferine inhibited autophagy in GO orbital fibroblasts, as indicated by the suppression of IL‐13‐induced autophagosome formation, overexpression of autophagy markers, increased LC3‐II/LC3‐I levels and finally down‐regulation of p62. Neferine suppressed IL‐13‐induced inflammation, ROS generation, fibrosis and adipogenic differentiation in GO patient‐derived orbital fibroblasts. The anti‐inflammatory, antioxidant and antiadipogenic effects of neferine were accompanied by the up‐regulation of Nrf2. These results indicated that orbital tissue remodelling and inflammation in GO may be mediated by autophagy, and neferine suppressed autophagy‐related inflammation and adipogenesis through a mechanism involving Nrf2.
PPARγ/NF‐κB and TGF‐β1/Smad pathway are involved in the anti‐fibrotic effects of levo‐tetrahydropalmatine on liver fibrosis
Authors: Yu Qiang , Cheng Ping , Wu Jianye , Guo Chuanyong 
Published: January 2021

AbstractLiver fibrosis is a necessary stage in the development of chronic liver diseases to liver cirrhosis. This study aims to investigate the anti‐fibrotic effects of levo‐tetrahydropalmatine (L‐THP) on hepatic fibrosis in mice and cell models and its underlying mechanisms. Two mouse hepatic fibrosis models were generated in male C57 mice by intraperitoneal injection of carbon tetrachloride (CCl4) for 2 months and bile duct ligation (BDL) for 14 days. Levo‐tetrahydropalmatine was administered orally at doses of 20 and 40 mg/kg. An activated LX2 cell model induced by TGF‐β1 was also generated. The results showed that levo‐tetrahydropalmatine alleviated liver fibrosis by inhibiting the formation of extracellular matrix (ECM) and regulating the balance between TIMP1 and MMP2 in the two mice liver fibrosis models and cell model. Levo‐tetrahydropalmatine inhibited activation and autophagy of hepatic stellate cells (HSCs) by modulating PPARγ/NF‐κB and TGF‐β1/Smad pathway in vivo and in vitro. In conclusion, levo‐tetrahydropalmatine attenuated liver fibrosis by inhibiting ECM deposition and HSCs autophagy via modulation of PPARγ/NF‐κB and TGF‐β1/Smad pathway.
Xanthatin synergizes with cisplatin to suppress homologous recombination through JAK2/STAT4/BARD1 axis in human NSCLC cells
Authors: Zhang Jian , Yang Sheng , Guan Hongmei , Zhou Jueyu , Gao Yuan 
Published: January 2021

AbstractXanthatin (Xa) is a bicyclic sesquiterpene lactone identified from the plant Xanthium L. with impressive antitumor activity, but the role of Xa in non‐small cell lung cancer (NSCLC) is not known. Here we found that Xa inhibits proliferation, migration, invasion and induces apoptosis in NSCLC cells. RNA sequencing and Gene set enrichment analysis revealed that Xa significantly activates p53 pathway and suppresses E2F targets, G2M checkpoint and MYC targets in A549 cells. Among these changed genes, the down‐regulated gene BARD1 triggered by Xa was identified as a candidate involved in Xa’s antitumor effect because of its vital role in homologous recombination (HR). Further studies demonstrated that Xa inhibits HR through the BARD1/BRCA1/RAD51 axis, which enhances cell sensitivity to cisplatin. Mechanistic studies showed that Xa inhibits BARD1 through the JAK2/STAT4 pathway. Our study revealed that Xa is a promising drug to treat NSCLC, especially in combination with conventional chemotherapy.
Electronic dashboard‐based remote glycemic management program reduces length of stay and readmission rate among hospitalized adults
Authors: Sheen Yi‐Jing , Huang Chien‐Chung , Huang Shih‐Che , Lin Ching‐Heng , Lee I‐Te , H‐H Sheu Wayne 
Published: January 2021

AbstractAims/IntroductionCurrently, the impact of hospital‐wide glycemic control interventions on length of hospital stay (LOS) and readmission rates are largely unknown. We investigated the impact of a 4‐year hospital‐wide remote glycemic management program on LOS and 30‐day readmission rates among hospitalized adults who received glucose monitoring.Materials and MethodsIn this retrospective study, hospitalized patients who received glucose monitoring were classified into groups 1 (high glucose variability), 2 (hypoglycemia), 3 (hyperglycemia) and 4 (relatively stable). The monthly percentage changes, and average monthly percentage changes of hyperglycemia, hypoglycemia and treat to target were determined using joinpoint regression analysis.ResultsA total of 106,528 hospitalized patients (mean age 60.9 ± 18.5 years, 57% men) were enrolled. We observed a significant reduction in the percentage of inpatients in poor glycemic control groups (groups 1, 2 and 3, all P < 0.001), and a reciprocal increase in the relatively stable group (group 4) from 2016 to 2019. We found a significant reduction in LOS by 11.4% (10.5–9.3 days, P = 0.002, after adjustment for age, sex, and admission department). The 30‐day readmission rate decreased from 29.9% to 29.3%, mainly among those in group 4 in 2019 (P < 0.001 after adjustment of sex, age, admission department and LOS).ConclusionsImproved glycemic control through a hospital‐wide electronic remote glycemic management system reduced LOS and 30‐day readmission rates. Findings observed in this study might be associated with the reduction in cost of avoidable hospitalizations.
On‐label use of sodium–glucose cotransporter 2 inhibitors might increase the risk of diabetic ketoacidosis in patients with type 1 diabetes
Authors: Horii Takeshi , Oikawa Yoichi , Atsuda Koichiro , Shimada Akira 
Published: January 2021

AbstractAims/IntroductionThis study aimed to investigate the risk of diabetic ketoacidosis (DKA) in insulin‐treated type 1 diabetes patients administered sodium–glucose cotransporter 2 (SGLT2) inhibitors in real‐world clinical practice.Materials and MethodsWe carried out a real‐world, retrospective, observational cohort study using Japanese Medical Data Vision, a diagnosis procedure combination database. We identified insulin‐treated adult type 1 diabetes patients enrolled from December 2018 to October 2019. We assessed the incidence and risk of DKA in type 1 diabetes patients using SGLT2 inhibitors in an ‘on‐label’ manner. Cox multivariate regression analyses were carried out to determine clinical factors linked to SGLT2 inhibitor‐associated DKA.ResultsOf 11,475 type 1 diabetes patients, 1,898 (16.5%) were prescribed SGLT2 inhibitors. DKA occurred in 139 (7.3%) of these patients, with 20.2 incidences per 100 person‐years. These patients also showed significantly higher DKA rates than did those not receiving SGLT2 inhibitors (hazard ratio 1.66, 95% confidence interval 1.33–2.06; P < 0.001). The mean time until DKA onset in SGLT2 inhibitor‐treated type 1 diabetes patients was 30.6 ± 30.1 days. The risk of SGLT2 inhibitor‐associated DKA increased in type 1 diabetes patients irrespective of sex, age or body mass index. However, the risk did not increase in type 1 diabetes patients receiving continuous subcutaneous insulin infusion, which warrants further investigation because of the small number of type 1 diabetes patients receiving continuous subcutaneous insulin infusion.Conclusions‘On‐label’ SGLT2 inhibitor use might increase DKA risk among insulin‐treated type 1 diabetes patients irrespective of sex, age or body mass index. Both type 1 diabetes patients and healthcare providers should be wary of DKA, especially during the first month of initiating SGLT2 inhibitors.